Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Gilead's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
63.08 +0.50    +0.80%
24/06 - Closed. Currency in USD ( Disclaimer )
After Hours
63.02
-0.06
-0.10%
0:28:13 - Real-time Data
  • Volume: 8,851,584
  • Bid/Ask: 63.00 / 63.02
  • Day's Range: 61.85 - 63.13
Type:  Equity
Market:  United States
ISIN:  US3755581036 
CUSIP:  375558103
Gilead 63.08 +0.50 +0.80%
RankUsernameTotalClosedWinningWin %Chg. %
1neal macdougall77457.14+26.53%
2Epishkov Ivan222100+21.46%
3Mat Schoedel111100+18.23%
4Виктор Житинский66466.67+17.77%
5Yan Litosh111100+15.81%
6Scott Lampron111100+15.43%
7Славян Евстатиев111100+12.96%
8Michael Fanning444100+12.29%
9Leo Stanislavovich111100+11.97%
10Francesco Tocco111100+11.81%
11Wenbo Chen222100+11.36%
12Leni Wijaya111100+11.3%
13Haris Turalic111100+11.28%
14Анна Аносова111100+11.13%
15Александр Fktrcfylh333100+10.96%
16Alvaro Santillan Nava111100+10.68%
17Othon Boerner222100+10.54%
18Thomas Schifferl222100+10.44%
19Pedro Costa111100+10.05%
20Igor Milovanov111100+10.01%
21Jeremy Swainston111100+9.85%
22gabriele chiappa111100+9.47%
23ZI JAM111100+9.06%
24Rogue Trader111100+8.49%
25Ramon Fernandez Garcia111100+8.3%
26Keith Reynolds111100+8.19%
27Slava Sergeevich222100+7.82%
28sisalvi chipuo222100+7.02%
29Jack Sparacio111100+6.92%
30Hu Raster111100+6.84%
31Κωνσταντίνος Βελισσάρης222100+6.78%
32Kaiser Donut111100+6.73%
33Giuseppe Mento111100+6.59%
34Charles Monroe222100+6.53%
35Александр Бантос111100+6.52%
36Alexander Karakashian111100+6.42%
37Ilkhom Khaitov22150+6.37%
38simone scelsa111100+6.36%
39Dario Lupi111100+6.18%
40Михаил Альтмарк111100+6.11%
41José Joaquín Loza Rodríguez66466.67+6.06%
42Сергей Соколов111100+6%
43ДМ ДМ33133.33+5.98%
44Νικοσ Σαρλησ111100+5.87%
45Francisco Sierra111100+5.8%
46John Odonoghue111100+5.75%
47Айрат Абдуллин111100+5.66%
48Роман Шевченко44375+5.57%
49Jonas Nhassengo111100+5.55%
50wongyu Lee111100+5.51%
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job GILD. bullish move forward
Ashraf Elgendy
Ashraf Elgendy Mar 07, 2021 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
RM RM
RM RM Mar 01, 2021 21:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up Again
Ken Laing
Ken Laing Oct 23, 2020 18:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to load up before the big rise coming next week
Iggy Maldon
Iggy Maldon Jul 30, 2020 20:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Classic pump n’ dump. What a shambles
RM RM
RM RM May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will reach above 95
Chili Daug
Chili Daug May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when? hahah
SAGAR AGARWAL
SAGAR AGARWAL May 15, 2020 14:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good time to accumulate.
Khizer Malik
Khizer Malik May 14, 2020 11:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
Willy Chin
Willy Chin Apr 23, 2020 18:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
High chance to be trading above 90, good long stock
Viktor Veselý
Viktor Veselý Apr 12, 2020 7:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email